Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN044 in Advanced Solid Tumors
NCT04126590Phase 1Unknown
- Sponsor
- Changchun Intellicrown Pharmaceutical Co., Ltd.
- Start
- Jan 2020
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of KN044 in solid tumor (7 arms), sponsored by Changchun Intellicrown Pharmaceutical Co., Ltd. Primary endpoints: Dose-limiting toxicity up to 6 weeks, Adverse Events up to 210 days and 1 more. Status: unknown.
02
Drugs
KN044
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04126590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04126590.